Evaluation of the safety of live attenuated influenza vaccine (LAIV) in children and adolescents with asthma and high-risk conditions: a population-based prospective cohort study conducted in England with the Clinical Practice Research Datalink.

ABSTRACT:

Objectives

To assess the safety of live attenuated influenza vaccine (LAIV) in children in high-risk groups.

Design

Non-interventional cohort study.

Setting

England during 2013-2014 and 2014-2015 influenza seasons.

Participants

LAIV recipients identified from the Clinical Practice Research Datalink, aged 2-17 years, and with at least one underlying high-risk condition. LAIV recipients were matched with inactivated influenza vaccine (IIV) recipients and unvaccinated controls.

Primary outcome measures

Primary safety endpoints were any hospitalisation documented in the linked Hospital Episodes Statistics database within 42 days and up to 6 months after vaccination.

Results

11 463 children and adolescents were included: 4718 received the trivalent LAI

SUBMITTER: Caspard H 

PROVIDER: S-EPMC6292422 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature